

1 **Longitudinal *in vivo* micro-CT-based approach allows spatio-temporal characterization of**
2 **fracture healing patterns and assessment of biomaterials in mouse femur defect models**

3 Esther Wehrle¹, Duncan C Tourolle né Betts¹, Gisela A Kuhn¹, Erica Floreani¹, Malavika H
4 Nambiar¹, Bryant J Schroeder¹, Sandra Hofmann^{1,2}, Ralph Müller^{1*}

5 ¹ Institute for Biomechanics, ETH Zurich, Zurich, Switzerland, ² Department of Biomedical
6 Engineering and Institute for Complex Molecular Systems, Eindhoven University of
7 Technology, The Netherlands.

8

9

10 **Corresponding author:**

11 Ralph Müller, PhD

12 Institute for Biomechanics

13 ETH Zurich

14 Leopold-Ruzicka-Weg 4

15 8093 Zurich, Switzerland

16 Email: ram@ethz.ch

17

18

19 **Abstract**

20 Thorough preclinical evaluation of functionalized biomaterials for treatment of large bone
21 defects is essential prior to clinical application. Using *in vivo* micro-computed tomography
22 (micro-CT) and mouse femoral defect models with different defect sizes, we were able to
23 detect spatio-temporal healing patterns indicative of physiological and impaired healing in
24 three defect sub-volumes and the adjacent cortex. The time-lapsed *in vivo* micro-CT-based
25 approach was then applied to evaluate the bone regeneration potential of functionalized
26 biomaterials using collagen and BMP-2. Both collagen and BMP-2 treatment led to distinct
27 changes in bone turnover in the different healing phases. Despite increased periosteal bone
28 formation, 87.5% of the defects treated with collagen scaffolds resulted in non-unions.
29 Additional BMP-2 application significantly accelerated the healing process and increased the
30 union rate to 100%. This study further shows potential of time-lapsed *in vivo* micro-CT for
31 capturing spatio-temporal deviations preceding non-union formation and how this can be
32 prevented by application of functionalized biomaterials.

33 This study therefore supports the application of longitudinal *in vivo* micro-CT for
34 discrimination of normal and disturbed healing patterns and for the spatio-temporal
35 characterization of the bone regeneration capacity of functionalized biomaterials.

36

37 Introduction

38 Regeneration and healing of large bone defects (e.g. caused by trauma, infection, tumor
39 resection, congenital skeletal disorders) is a treatment challenge in orthopedic surgery with
40 as much as 10-20% of patients experiencing delayed or non-unions¹⁻³. Recent advances in
41 tissue engineering and material sciences (e.g. 3D-bioprinting) enabled the development of
42 diverse biomaterials, which can be functionalized with biochemical factors (e.g. growth
43 factors) and combined with cell therapeutic approaches³⁻⁵. In order to facilitate the clinical
44 application of these innovative approaches for the treatment of large bone defects, their bone
45 regeneration capacity needs to be systematically and thoroughly characterized in preclinical
46 studies⁶⁻⁸. For this purpose, critical size defect models have been developed for load-bearing
47 and non-load-bearing bones in small and large animals^{7,9-13}. So far, most of these studies
48 focused their evaluation on end-point radiological and histological analysis¹⁴⁻¹⁶. However,
49 recent studies indicate that longitudinal non-invasive imaging could improve the evaluation
50 of a biomaterial's bone regeneration capacity, due to the ability to follow the regeneration
51 process in the same animal over time, thereby also reducing animal numbers according to the
52 3R's of animal welfare^{17,18}. Particularly, *in vivo* micro-CT was shown to be suitable for the
53 assessment of bone tissue formation and mineralization after biomaterial application in
54 critical size defect models¹⁷⁻¹⁹. A further development is the consecutive registration of time-
55 lapsed *in vivo* images²⁰. We recently developed a longitudinal *in vivo* micro-CT-based
56 approach for healing-phase-specific monitoring of fracture repair in mouse femur defect
57 models²¹. Registration of consecutive scans using a branching scheme (bridged vs. unbridged
58 defect) combined with a two/multi-threshold approach enabled the assessment of localized
59 bone turnover and mineralization kinetics relevant for monitoring callus remodelling^{21,22}.

60 Furthermore, we showed that longitudinal *in vivo* micro-CT imaging itself did not significantly
61 affect callus formation and remodelling²².

62 It is well accepted that longitudinal non-invasive imaging of the healing process is
63 advantageous compared to cross-sectional study designs²². In order to apply *in vivo* micro-CT-
64 based longitudinal monitoring approaches for the evaluation of functionalized biomaterials, it
65 has to be assessed, whether these approaches allow for reliable discrimination between
66 normal and impaired healing conditions (e.g. critical-sized defects). So far, preclinical studies
67 were often not able to reliably capture the bone healing potential of biomaterials due to
68 limitations in study design: (I) cross-sectional setup, (II) assessment not considering defect
69 sub-volumes, (III) assessment not specific to the healing phases.

70 Therefore, this study assesses whether our recently developed time-lapsed micro-CT based
71 monitoring approach is suitable for discrimination of healing patterns associated with
72 physiological and impaired bone healing conditions using mouse femur defect models with
73 different gap sizes. In a second step, we evaluated whether the time-lapsed *in vivo* micro-CT-
74 based monitoring approach is suitable for profound characterization of the bone regeneration
75 capacity of functionalized biomaterials using well characterized porous collagen scaffolds and
76 bone morphogenetic protein (BMP-2) as gold standard

77

78 **Results**

79 In Experiment 1, we assessed the potential of time-lapsed *in vivo* micro-CT for reliable
80 discrimination between physiological and impaired fracture healing patterns. We compared
81 the healing process (week 0-6) in mice receiving either a small (0.9mm, n=10) or large femur

82 defect (2mm, n=8; Fig. 1; Supplementary Video 1). Via registration of consecutive micro-CT
83 scans, structural and dynamic callus parameters were followed in three callus sub-volumes
84 (defect center, DC; defect periphery, DP; cortical fragment periphery, FP) and the adjacent
85 cortical fragments (FC) over time (Fig. 1, 2). In Experiment 2, we applied the same time-lapsed
86 *in vivo* imaging approach to assess the bone regeneration capacity of collagen scaffolds (n=8)
87 and collagen scaffolds+BMP-2 (n=8; Fig. 3, 4, Supplementary Video 2; for detailed study design
88 see Supplementary Table S1).

89 **General physical observation**

90 Post-operative monitoring was performed with a scoring system defined in license number
91 36/2014 (Kantonales Veterinärämte Zürich, Zurich, Switzerland), evaluating the following
92 parameters: social behaviour, body position, motion, load bearing of operated limb, habitus,
93 surgery wound. Scoring values: 0-4 (0=normal, 4=severely impaired, end-point criteria: scored
94 4 in one category or overall score ≥ 8). Monitoring schedule: evening of surgery day, day 1-3:
95 morning and evening, day 4 until end of experiment: 3x/week, daily if scored ≥ 2 in one
96 criterion. All mice recovered rapidly from surgery. However, one animal from the 0.9mm
97 defect group only showed minor load bearing of the operated limb in the first post-operative
98 week, which then gradually increased, reaching normal values after 2 weeks. The body weight
99 did not significantly change during the healing period and did not differ between the groups
100 in Experiment 1 and 2 (see Supplementary Fig. 1 and 2). Social interaction between mice and
101 nesting behaviour did not differ from pre-surgical observations and were similar for animals
102 from all groups.

103

104 **VOIs for evaluation by time-lapsed *in vivo* micro-CT**

105 **Experiment 1:**

106 In order to exclude bias in the further micro-CT analyses, we compared the size of the two
107 central VOIs (DC, FC) used for normalization of CT parameters (depicted in Fig. 2) between
108 groups. One animal from the 2.0mm group could not be included in the analysis due to
109 incorrect registration caused by differences in leg alignment between micro-CT scans. The two
110 central VOIs encompassed the following volume for the 0.9mm group (n=10) and the 2.0mm
111 group (n=7) with significant group differences given in brackets: $1.64\pm 0.19\text{mm}^3$ vs.
112 $3.45\pm 0.18\text{mm}^3$ for DC ($p<0.0001$), and $3.18\pm 0.12\text{mm}^3$ vs. $0.94\pm 0.30\text{mm}^3$ for FC ($p<0.0001$).

113 **Experiment 2:**

114 The DC and FC VOIs encompassed the following volume for the collagen group (n=8) and the
115 collagen+BMP-2 group (n=8): $3.09\pm 0.22\text{mm}^3$ vs. $3.15\pm 0.22\text{mm}^3$ for DC and $1.25\pm 0.26\text{mm}^3$ vs.
116 $1.47\pm 0.19\text{mm}^3$ for FC. No significant group differences in VOI size were detected between the
117 two groups.

118

119 **Longitudinal monitoring of fracture healing by time-lapsed *in vivo* micro-CT in non-critical**
120 **and critical-sized femur defects (Experiment 1)**

121 In both groups the repeated micro-CT scans (1x/week, Fig. 1, Supplementary Video 1) covered
122 the period from the day of the defect surgery (d0) until post-operative week 6. In the 0.9mm
123 group, distinct callus characteristics indicative of the different healing phases (inflammation,
124 repair, remodelling) were seen in the three callus VOIS (DC, DP, FP; Fig. 1 and Fig. 2) as
125 previously described in the same femur defect model²². Specifically, a strong increase in bone
126 formation with maximum values in week 1-2 (BFR: DC - $3.67\pm 1.50\%$) and week 2-3 (BFR: DP -
127 $2.44\pm 1.31\%$, FP - $2.50\pm 0.89\%$; Fig. 2) indicated the progression from the inflammation to the

128 repair phase. This triggered bone resorption with maximum values seen in week 2-3 (BRR: DC
129 - $1.15 \pm 0.48\%$) and week 3-4 (BRR: DP - $0.82 \pm 0.74\%$, FP - $0.86 \pm 0.48\%$) indicating progression to
130 the remodelling phase. In all callus VOIs, a significant increase ($p < 0.0001$) in bone volume was
131 seen over time with maximum values observed in week 4 (BV/TV: DC - $44 \pm 9\%$, DP - $24 \pm 10\%$,
132 FP - $29 \pm 8\%$). From week 2 onwards, the fraction of highly mineralized bone continuously
133 increased in all callus VOIs until the study endpoint (week 6).

134 In the 2.0mm defect group, only a slight onset in bone formation was seen in the callus VOIs
135 from week 0-1 to week 1-2 without characteristic peak values in the further healing process
136 (Fig. 1 and 2). We could also not observe any significant gain in bone volume throughout the
137 healing period, indicating an impaired and delayed healing pattern. Nevertheless, we saw a
138 continuous increase in the fraction of highly mineralized bone in all callus VOIs, indicating no
139 substantial disturbances of callus mineralization, despite the small callus volume. Comparison
140 of both groups (0.9mm defect, 2.0mm defect) showed similar patterns in healing initiation
141 with bone formation, first starting in the defect center (DC) and the cortical fragment
142 periphery (FP) from week 0-1 to week 1-2. However, in the DC VOI the increase in bone
143 formation (6x) was significantly lower ($p = 0.001$) in the 2mm group compared to the 0.9mm
144 group (19x) and the bone formation rates then remained stable at low values ($\leq 0.95\%/day$)
145 throughout the healing period associated with only little endosteal callus formation. In the FP
146 VOI, the increase in bone formation from week 0-1 to week 1-2 was similar for both groups,
147 but the 2.0mm defect group then showed a sudden decline (-40%) in bone formation (week
148 1-2 vs week 2-3) leading to premature cessation of periosteal callus formation. In the defect
149 periphery (DP), hardly any callus formation (BFR $\leq 0.21\%/day$) was seen in the 2.0mm defect
150 group throughout the healing period leading to significantly smaller callus dimensions

151 compared to the 0.9mm group from week 3 until the study end ($p=0.0001$). With respect to
152 bone resorption, no significant differences between the two defect groups were seen in the
153 early healing period (week 0-1, week 1-2) in any of the callus sub-volumes. However, in the
154 later healing period, bone resorption was significantly lower in the 2.0mm defect group
155 compared to the 0.9mm defect group in DC (week 2-3: $p=0.047$, week 4-5: $p=0.0064$), FP
156 (week 2-3: $p=0.0045$, week 5-6: $p=0.0048$) and DP (week 4-5: $p=0.0157$, week 5-6: $p=0.0177$)
157 VOIs, indicating impaired bone remodelling. By week 6, not only the bone volume, but also
158 the fraction of highly mineralized bone was lower in all callus sub-volumes in the 2.0mm defect
159 group compared to the 0.9mm defect group with significant differences ($p=0.0383$) being
160 observed in the DP sub-volume (BV_{645}/BV_{395} : 2.0mm group - $63\pm 11\%$, 0.9mm group - $82\pm 4\%$).

161

162 To assess functional healing outcome, we particularly focused on the defect VOIs (DC+DP)
163 which are most important for evaluating later healing time points during the remodelling
164 phase of fracture healing. The previously observed differences in bone turnover, bone volume
165 and mineralization between the two groups also affected cortical bridging. According to the
166 standard clinical evaluation of X-rays, the number of bridged cortices per callus was evaluated
167 in two perpendicular planes and animals with ≥ 3 bridged cortices were categorized as healed.
168 Cortical bridging first occurred by week 3 in 70% of the animals in the 0.9mm defect group,
169 whereas none of the animals in the 2.0mm group showed bridged cortices at this time point
170 (Table 1). By week 6, 90% of the 0.9mm defects were categorized as healed with only 1 defect
171 being classified as non-union. In contrast, in the 2.0mm defect group only 1 animal showed
172 cortical bridging and 87.5% manifested as non-unions.

173

174 Bone turnover in the cortical fragments (FC) showed a similar pattern in both groups, without
175 characteristic peak values in bone formation and resorption rates. Specifically, maximum bone
176 formation rates were significantly lower (0.9mm group: -80%, $p < 0.0001$, 2.0mm group: -58%,
177 $p = 0.004$) compared to those observed in the periosteal region (FP). Furthermore, a negative
178 bone turnover was seen with maximum resorption rates (BRR in week 2-3: $0.79 \pm 0.15\%$)
179 exceeding bone formation rates (BFR in week 2-3: $0.49 \pm 0.37\%$) in the 0.9mm group. This
180 resulted in a decrease in bone volume over time (0.9mm group: -19%, 2.0mm group: -57%).
181 Additionally, a significant 8% (0.9mm group, $p = 0.0017$) and 11% (2.0mm group, $p = 0.0072$)
182 decrease in the fraction of highly mineralized bone was seen from week 1 to week 3 suggesting
183 reorganization of the cortical bone adjacent to the forming and remodelling fracture callus.

184

185 **Longitudinal assessment of biomaterials by time-lapsed *in vivo* micro-CT in critical-sized**
186 **femur defects (Experiment 2)**

187 In the collagen group, no significant weekly changes in bone formation rate were seen in the
188 central defect VOIs (DC, DP; Fig. 3 and 4; Supplementary Video 2). Bone resorption rates
189 slightly but significantly increased during the early healing period (DC: 7.6x from week 0-1 to
190 week 1-2, DP: 4.3x from week 0-1 to week 1-2) and then decreased (DC) or remained stable
191 (DP) from week 2-3 to week 5-6. This led to only little callus formation in these central VOIs,
192 as similarly seen in the 2mm defect group from Experiment 1, indicating an impaired endosteal
193 fracture healing pattern associated with the application of the collagen scaffolds. In the
194 periosteal VOI (FP), a significant 3.2x increase in bone formation rate was seen from week 0-
195 1 to week 1-2, which remained stable during the subsequent week, before decreasing after
196 week 2-3 reaching baseline values by week 5-6. No significant changes were seen in the bone

197 resorption rate throughout the healing process. Compared to the 2mm defect group from
198 Experiment 1, similar periosteal callus volumes were observed in the early healing period
199 (BV/TV in week 2: collagen group: $13.08 \pm 4.88\%$, 2mm defect group: $15.99 \pm 5.09\%$). In the
200 collagen group, the periosteal callus volume further increased (+53%) from week 2 to week 3,
201 whereas it decreased (-30%) in the 2mm defect group during the same period, suggesting
202 changes in periosteal callus formation potentially associated with the application of the
203 collagen scaffolds.

204 In the collagen+BMP-2 group, a similar healing pattern compared to the collagen group was
205 seen in the defect center (DC). Nevertheless, BMP-2 application led to a significantly 2.1x
206 increased bone formation rate in week 1-2 compared to the collagen group, which was also
207 associated with a transiently increased mineralized callus volume in this endosteal VOI in week
208 2. However, in week 6, both groups showed similar callus volumes and fraction of highly
209 mineralized bone, indicating only a slight and transient BMP-2 associated effect on callus
210 formation and remodelling in the defect center. In contrast, in DP and FP VOIs a completely
211 different picture was seen: compared to the collagen group, a sudden 17x (DP) and 3.6x (FP)
212 induction in BFR already from week 0-1 to week 1-2 was detected. This indicates that
213 collagen+BMP-2 scaffolds are able to induce bone formation at defect locations distant to the
214 cortical bone potentially allowing healing of large defects. The BMP-2 induced increase in the
215 bone formation rate was higher but persisted shorter compared to the 0.9mm defect group
216 with uncompromised healing in Experiment 1. This led to a significant 318x (DP) and 9.1x (FP)
217 increase in bone volume by week 2 (DP: $p < 0.0001$; FP: $p = 0.0002$). The periosteal callus volume
218 significantly ($p < 0.0001$ for DP and FP) exceeded the values of the collagen group and was also
219 higher compared to the 0.9mm group from Experiment 1. In both VOIs a significant 63x (DP)

220 and 10x (FP) increase in bone resorption was seen from week 1-2 to week 2-3 ($p < 0.0001$ for
221 both VOIs), indicating early onset of callus remodelling. The bone resorption rates then
222 remained at significantly higher levels compared to the collagen group and both groups from
223 Experiment 1, indicating pronounced callus remodelling in the collagen+BMP-2 group. The
224 fraction of highly mineralized tissue remained significantly lower in the collagen+BMP-2 group
225 indicating that the remodelling process was still ongoing, whereas the bone healing process
226 had finished in all other groups.

227 Despite the BMP-2 associated improved healing outcome, the healing pattern was completely
228 different compared to the 0.9mm defect group with uncompromised healing. In the
229 collagen+BMP-2 group bone formation mainly took place in the periosteal regions and the
230 defect periphery, whereas in the 0.9mm defect group bone formation mainly took place in the
231 defect center. The collagen group showed similar values compared to the 2.0mm defect group
232 indicating impaired healing, suggesting that the collagen scaffold might have blocked
233 endosteal callus formation.

234 In the FC VOI, we saw a similar pattern in all indices for the collagen and the collagen+BMP-2
235 group without any significant differences between groups. Specifically, the bone formation
236 rate did not significantly change over time in both groups. Similar to the 2mm defect group
237 from Experiment 1, a significant induction of bone resorption rate was seen from week 0-1 to
238 week 1-2. From week 1 until the study end, the bone volume significantly ($p < 0.0001$)
239 decreased in both groups (collagen group: -48%, collagen+BMP-2 group: -44%). Furthermore,
240 a significant decline in the fraction of highly mineralized bone was observed in both groups
241 from week 0 to week 6 (collagen group: -9%, $p = 0.0002$; collagen+BMP-2 group: -13%,
242 $p < 0.0001$), as similarly observed for the 2mm defect group in Experiment 1 (-16%, $p = 0.003$).

243

244 Cortical bridging occurred by week 2 in 100% of the animals in the collagen+BMP-2 group,
245 whereas no animal in the collagen group showed bridged cortices at this time point (Table 2).
246 In the BMP-2 treated defects, cortical bridging also occurred 1 week earlier compared to the
247 0.9mm defect group from Experiment 1. In contrast, in the collagen group only 1 animal
248 showed cortical bridging and 87.5% manifested as non-unions.

249

250 **Histology**

251 As shown by Safranin-O staining six weeks after osteotomy, hardly any cartilage residuals were
252 present in the defect region in all groups, indicating progression of the healing process to the
253 final remodelling stage (Fig. 5, Row 1 and 2). To visualize potential remnants of the collagen
254 scaffolds in Experiment 2, 1-2 samples/group were stained with Sirius-Red (Fig. 5, Row 3 and
255 4). For comparisons, we also included sections of the original collagen scaffolds (Fig. 5, Row
256 5), where red color of the filaments is indicative of collagen. In contrast, no red signal
257 indicative of collagen was seen in the defect center of both groups (Fig. 5, Row 4). This
258 suggested complete degradation of the scaffolds with accumulation of fat cells in the defect
259 (unbridged defects in collagen group and in the restored medullary cavity, bridged defects in
260 the collagen+BMP-2 group; Fig. 5, Row 4).

261

262 **Discussion**

263 In this study, we showed that time-lapsed *in vivo* micro-CT allows for spatio-temporal
264 discrimination between physiological and impaired fracture healing patterns in a mouse femur
265 defect model. For this purpose, we compared the healing pattern in three callus sub-volumes

266 and the adjacent cortical fragments in a small (0.9mm) and a large (2.0mm) defect group using
267 a previously developed two-threshold density micro-CT protocol ^{21,22}. In a second step, we
268 applied the micro-CT based monitoring approach for the characterization of the bone
269 regeneration capacity of functionalized biomaterials using porous collagen scaffolds +/- bone
270 morphogenetic protein (BMP-2).

271 By registering consecutive scans, we were able to include dynamic parameters such as bone
272 formation and resorption in our micro-CT based monitoring approach as previously described
273 ²¹. In the small defect group (0.9mm), this allowed for characterization of the different healing
274 phases seen by changes in formation and resorption in the osseous callus volume. Specifically,
275 we saw that the initiation of bone formation (maximum in week 1-2), indicating the onset of
276 the reparative phase, triggered bone resorption (maximum in week 2-3) thereby initiating the
277 remodelling phase. Maximum osseous callus volumes were observed in week 3, which
278 remained stable until the study end, while the callus mineralization increased throughout the
279 healing period. The observed bone turnover (bone formation triggering bone resorption) and
280 callus maturation (increasing mineralization of initial callus) patterns are similar to a recent
281 study in 1.5mm defects, which showed an uncompromised healing pattern ²². However, the
282 smaller defect size (- 40%) in the current study, changed the temporal occurrence of peaks in
283 bone formation and resorption, which were seen one week earlier compared to the previous
284 study in 1.5mm defects, indicating faster healing progression.

285 As expected from literature ²³, the larger defects (2.0mm) showed impaired healing
286 predominantly leading to non-unions in 7 of 8 animals at the study end (Fig. 2, Table 1). This
287 is in line with a study by Zwingenberger et al. ²³, which previously showed a strong correlation
288 of the defect size and non-unions assessed via *in vivo* X-ray measurements as well as end point

289 micro-CT and histological analyses in a similar defect model. Via registration of consecutive *in*
290 *vivo* micro-CT scans, we were now able to reveal and visualize the preceding spatio-temporal
291 deviations in callus formation and remodelling compared to the uncompromised healing
292 pattern seen in the 0.9mm defect group. Deviations from normal healing occurred in all callus
293 sub-volumes (defect center, defect periphery, cortical fragment periphery), although initiation
294 of bone formation was not changed spatio-temporally, starting in the same sub-volumes (DC,
295 FP) and at the same time (week 0-1 to week 1-2). However, the rise in bone formation was
296 significantly lower endosteally and the duration of the bone formation was reduced
297 periosteally compared to the 0.9mm defect group. This also led to only small endosteal and
298 peripheral callus dimensions with the periosteal callus volume even decreasing to baseline
299 values by the study end. Under normal healing conditions, callus formation in this femur
300 defect model proceeds from both the endosteal and the periosteal regions to the defect
301 periphery^{22,24}, whereas in large defects hardly any bone formation was seen here, suggesting
302 early termination of the fracture healing process.

303 It is important to separately look at the adjacent cortical fragments²², where we previously
304 saw an opposite trend in bone turnover compared to the callus sub-volumes. Whereas bone
305 formation was the dominant factor in the callus VOIs, bone resorption was the main factor in
306 the adjacent cortex. In the current study, increased defect size was associated with a
307 significant higher decline in cortical bone volume (-67% vs. -19%) and bone mineral density (-
308 16% vs. -6%; Fig. 1 and Fig. 2). Peri-fracture bone resorption and demineralization of cortical
309 bone have also been previously reported in preclinical and clinical studies and were associated
310 with stiff fixation leading to stress shielding of the bone^{25,26}. Our recently developed time-

311 lapsed *in vivo* micro-CT monitoring approach therefore allowed to precisely characterize the
312 spatio-temporal changes in structural and dynamic callus parameters preceding non-unions.
313 In a next step, we applied this monitoring approach to evaluate the bone regeneration
314 potential of biomaterials using collagen +/- BMP-2 as test materials. We selected collagen as
315 test material due to its wide usage in scaffolds intended for promotion of bone regeneration
316 and the comprehensive literature on its performance in *in vitro*, preclinical and clinical
317 applications ²⁷⁻²⁹. In our study, the application of collagen scaffolds did not significantly
318 improve bone regeneration compared to empty defects of the same size, with the same non-
319 union rates being observed at the study end (87.5% in both groups). Although periosteal bone
320 formation was more pronounced in the collagen group, the fracture healing outcome was not
321 different between groups. This is in line with previous bone defect studies in different rodent
322 models (loaded and non-loaded bones) reporting no significant effect of collagen scaffolds on
323 bone regeneration with incomplete bone union or non-unions at the study end ^{30,31}. Similarly,
324 in large animal models collagen scaffolds either failed to prevent non-unions ³² or to restore
325 the mechanical bone properties ³³. The low regeneration potential of collagen scaffolds has
326 been attributed to a general lack of bioactivity of collagen despite its overall favorable features
327 such as low antigenicity, high biodegradability and high biocompatibility ²⁷⁻²⁹. Furthermore,
328 studies indicate a high relevance of the pore size in the collagen scaffolds, with smaller pores
329 potentially being affected by cellular occlusion, and preventing cellular penetration, production
330 of extracellular matrix and neovascularization of the inner areas of the scaffold ²⁸. In contrast,
331 larger pores have been associated with low mechanical scaffold properties and early scaffold
332 degradation ^{34,35}. A major limitation of most studies is that they did not include empty defect

333 and positive controls, which would be essential for better understanding of specific changes
334 in healing patterns mediated by different biomaterials.

335 To further promote bone healing, scaffolds have been incubated in solutions containing
336 growth factors (e.g. BMP-2, BMP-7; ^{36,37}). Especially BMP-2 has been widely applied in
337 preclinical studies to promote healing of critical sized defects (for review see ³⁸) and in clinical
338 settings. However, studies reported BMP-2 associated adverse events and complications (e.g.
339 antibody formation, inflammation, ectopic bone formation, carcinogenicity ³⁹⁻⁴¹). Therefore,
340 using low BMP-2 dosages seems crucial in order to avoid adverse effects while preserving its
341 osteoanabolic potential ⁴². So far preclinical studies used a wide range of BMP-2 dosages (0.1-
342 150.000 µg BMP-2 per defect in small animals as summarized in a comprehensive review by
343 Gothard et al. ³⁸). In this study, we therefore down-scaled the BMP-2 dosages from previous
344 studies (low BMP-2 dosages with beneficial effect on bone healing; 10/75 µg BMP-2 per defect
345 ^{43,44}) to the volume of our scaffold (2 µg BMP-2 per defect). Similar to other studies ³⁸, BMP-
346 2 application significantly accelerated the healing process leading to early cortical bridging.
347 However, when looking at the defect sub-volumes separately, we saw that the spatio-
348 temporal healing pattern largely differed from the physiological healing pattern seen in the
349 0.9mm group. In the collagen+BMP-2 group the increase in the bone formation rate was
350 higher but persisted for a shorter amount of time compared to the 0.9mm defect group.
351 Furthermore, bone formation mainly took place in the periosteal regions and the defect
352 periphery, whereas in the 0.9mm defect group bone formation was predominantly seen in the
353 defect center. This supports the assumption that the collagen scaffold itself might have
354 hindered cells from migrating into the defect center. In line with other studies ^{30,45}, the
355 collagen scaffolds were degraded in both groups by the end of the study as shown by absence

356 of collagen fibers in the defect center via Sirius Red staining of histological sections.
357 Accumulation of fat cells inside the formed cortical shell (unions) or in the defect center (non-
358 unions) indicated differentiation of mesenchymal stem cells (MSCs) towards the adipogenic
359 lineage in the later healing period. Concluding from the time-lapsed *in vivo* micro-CT
360 evaluation, strong BMP-2 induced bone formation associated with osteogenic differentiation
361 of MSCs was only transiently observed in the early healing period. Removal of the BMP-2
362 induced stimulus in later healing phases might have caused a change from osteogenic to
363 adipogenic differentiation of MSCs. This shift might have been further strengthened by stress
364 shielding of the defect region associated with stiff external fixation ⁴⁶.
365 Our study therefore shows that sub-volume specific characterization of functionalized
366 biomaterials seems crucial for assessing their bone regeneration potential. The study further
367 indicates that time-lapsed *in vivo* micro-CT combined with our recently developed two-
368 threshold density approach should be used in future studies to identify parameters for
369 prediction of non-unions in early healing phases. Via registration of consecutive scans as
370 described recently, we were able to precisely characterize and understand which spatio-
371 temporal deviations led to non-union formation and how this was prevented by BMP-2
372 application. Using collagen and BMP-2 as test materials, the time-lapsed *in vivo* micro-CT-
373 based monitoring approach was shown to be suitable for spatio-temporal assessment of callus
374 formation and remodelling patterns and could be used in future studies to characterize and
375 precisely understand the regeneration capacity of functionalized biomaterials.
376 The current study has several limitations. We did not track the degradation of the collagen
377 scaffolds over time and only performed end-point histological assessment of collagen
378 residuals via Sirius Red staining. Future studies should apply fluorescent biomaterials and

379 reporters, which could be visualized via *in vivo* optical imaging⁴⁷⁻⁴⁹. We did also not measure
380 the BMP-2 release kinetics. This could be similarly achieved via the use of labeled growth
381 factors⁵⁰ in combination with multimodal imaging (e.g. optical imaging, PET, SPECT, micro-
382 CT)^{17,51}. Furthermore, in order to reliably create critical-sized defects, the defect size would
383 need to be increased by ca. 25% in future studies.

384 Nevertheless, application of time-lapsed *in vivo* micro-CT allows faster and more precise
385 evaluation of biomaterials for bone regeneration, thereby also reducing the animal numbers
386 involved according to the 3R's of animal welfare. It could further be used for early prediction
387 of non-union formation and identification of biomarkers. The approach could be
388 supplemented with the registration of 2D-histology section into the 3D-micro-CT volume⁵²,
389 potentially allowing for a spatio-temporal understanding of molecular and cellular changes
390 induced by different biomaterials. To better mimic the clinical situation, future studies should
391 also assess the performance of biomaterials under load application, which could be achieved
392 using a recently developed loading fixator⁵³. By combining our *in vivo* time-lapsed micro-CT
393 based monitoring approach with individualized loading regimes, this would allow for thorough
394 characterization of biomaterials under clinically relevant loading conditions.

395 To conclude, *in vivo* time-lapsed micro-CT allows (1) spatio-temporal discrimination between
396 normal and disturbed healing patterns relevant for the detection of distinct features
397 associated with different medical conditions and (2) spatio-temporal characterization of the
398 bone regeneration capacity of functionalized biomaterials.

399

400 **Materials and Methods**

401 **Animals**

402 All animal procedures were approved by the local authorities (license number: 36/2014;
403 Kantonales Veterinäramt Zürich, Zurich, Switzerland). We confirm that all methods were
404 carried out in accordance with relevant guidelines and regulations (Swiss Animal Welfare Act
405 and Ordinance (TSchG, TSchV)) and reported considering ARRIVE guidelines. Female 12 week-
406 old C57BL/6J mice were purchased from Janvier (Saint Berthevin Cedex, France) and housed
407 in the animal facility of the ETH Phenomics Center (EPIC; 12h:12h light-dark cycle,
408 maintenance feed (3437, KLIBA NAFAG, Kaiseraugst, Switzerland), 5 animals/cage). At an age
409 of 20 weeks, all animals received a femur defect. In Experiment 1, one group of animals
410 received a small defect (defect length: $0.86\pm 0.09\text{mm}$, $n=10$) and a second group received a
411 large defect (defect length: $2.00\pm 0.19\text{mm}$, $n=8$; housing after surgery: 2-3 animals/cage). In
412 Experiment 2 both groups received a 2mm femur defect with application of either collagen
413 scaffolds ($d=2\text{mm}$, $h=2\text{mm}$; ILS, Saint Priest, France; $n=8$) or collagen scaffolds+BMP-2
414 ($2.5\mu\text{g/scaffold}$; PeproTech, London, UK; $n=8$). Perioperative analgesia (25 mg/L, Tramal®,
415 Gruenenthal GmbH, Aachen, Germany) was provided via the drinking water two days before
416 surgery until the third postoperative day. For surgery and micro-CT scans, animals were
417 anesthetized with isoflurane (induction/maintenance: 5%/1-2% isoflurane/oxygen).

418

419 **Femur defect**

420 An external fixator (Mouse ExFix, RISystem, Davos, Switzerland; stiffness: 24N/mm^{21}) was
421 positioned at the craniolateral aspect of the right femur and attached using four mounting
422 pins. First, the most distal pin was inserted approximately 2mm proximal to the growth plate,
423 followed by placement of the most proximal and the inner pins. Subsequently, a femur defect
424 was created using 1 and 2 Gigli wire saws for the small and the large defect, respectively.

425

426 **Time-lapsed *in vivo* micro-CT**

427 Immediate post-surgery correct positioning of the fixator and the defect was visualized using
428 a vivaCT 40 (Scanco Medical AG, Brüttisellen, Switzerland) (isotropic nominal resolution: 10.5
429 μm ; 55 kVp, 145 μA , 350 ms integration time, 500 projections per 180°, 21 mm field of view
430 (FOV), scan duration ca. 15 min). Subsequently, the defect region as well as the adjacent cortex
431 were scanned weekly (week 1-6) with the same settings and morphometric indices and
432 mineralization progression were determined in four volumes of interest (for details on
433 methods see ^{21,22}): defect center (DC), defect periphery (DP), cortical fragment center (FC),
434 and fragment periphery (FP). Data were normalized to the central VOIs: DC/DC, DP/DC, FC/FC,
435 FP/FC. Cortical bridging was assessed as previously described in ²².

436

437 **Animations**

438 To further visualize the defect healing process and the VOIs involved, 3-dimensional computer
439 renderings were created from the time-lapsed micro-CT data for one mouse in each respective
440 group across both experiments (0.9mm defect group, 2.0mm defect group, collagen scaffold,
441 collagen scaffold+BMP-2), then animated and captioned to create videos (Supplementary
442 Video 1, Supplementary Video 2). Bone mineral density data was single-value thresholded
443 ($\text{BMD} = 395 \text{ mg HA/cm}^3$) at each time point to create a binary array, simplifying the rendering
444 process. This binarized bone location data was interpolated using a Euclidean Distance
445 Transform, generating data for time points in between each weekly measurement. This data
446 was used to create smooth, animated transitions from one measurement to the next, for
447 visualization purposes, and was not used in any analysis. To indicate bone formation and

448 resorption between each time point, bone remodelling data from the time-lapsed *in vivo*
449 micro-CT method was taken ²¹. Depictions of the VOIs were rendered directly from their
450 location data used in this approach. All renderings of the 3D data were performed in ParaView
451 (Kitware, Version 5.6; Clifton Park, NY). All numerical analysis used for the animations was
452 done using custom Python 3 scripts. Video editing and captioning was done in Hitfilm Express
453 (FXhome, Version 13; Norwich, UK).

454

455 **Histology**

456 To exemplarily visualize the defect region, histology was performed in 1-2 animals/group. On
457 day 42 femurs were excised, the femoral head was removed, and the samples were placed in
458 4% neutrally buffered formalin for 24 hours and subsequently decalcified in 12.5% EDTA for
459 10-14 days. The samples were embedded in paraffin and 4.5 µm longitudinal sections were
460 stained with Safranin-O/Fast Green: Weigert's iron haematoxylin solution (HT1079, Sigma-
461 Aldrich, St. Louis, MO) - 4min, 1:10 HCl-acidified 70% ethanol - 10s, tap water - 5min, 0.02%
462 Fast Green (F7258, Sigma-Aldrich, St. Louis, MO) - 3min, 1% acetic acid - 10s, 0.1% Safranin-
463 O (84120, Fluka, St. Louis, MO) - 5min. In order to visualize remnants of the collagen scaffolds,
464 Sirius Red staining was performed in 1 animal from the collagen and 1 animal from the
465 collagen+BMP-2 group. For comparison, we also stained sections of the original collagen
466 matrix with Sirius-Red: Weigert's iron haematoxylin solution (HT1079, Sigma-Aldrich, St. Louis,
467 MO) - 8min, tap water - 10min, 1:9 Picro-Sirius Red solution (Picric acid: 80456, Fluka, St. Louis,
468 MO; Direct Red 80: AB133584, ABCR, Karlsruhe, Germany) - 1h, 5% acetic acid 2x10s. For both
469 stainings, images were taken with Slide Scanner Panoramic 250 (3D Histech, Budapest,
470 Hungary) at 20x magnification.

471

472 **Statistics**

473 CT analysis: Data were tested for normal distribution (Shapiro-Wilk-Test) and homogeneity of
474 variance (Levene-Test). Depending on the test outcome, group comparisons of data derived
475 at single time points were done by Student's t-test or Mann-Whitney U-tests (IBM SPSS
476 Statistics Version 23). For statistical evaluation of repeated measurements two-way ANOVA
477 with Geisser-Greenhouse correction and Bonferroni correction (GraphPad Prism 8) were
478 performed. The level of significance was set at $p < 0.05$.

479

480 **Author Contributions Statement**

481 The study was designed by E.W., G.A.K., S.H. and R.M.. The *in vivo* experiments were
482 performed by E.W., G.A.K. and E.F.. Histological stainings were performed by E.W. and M.H.N..
483 Data analyses were performed by E.W. and D.C.T.B.. Illustrations of VOIs and animations on
484 callus formation and remodelling were made by B.J.S.. The manuscript was written by E.W.
485 and reviewed and approved by all authors.

486

487 **Data availability**

488 All necessary data generated or analyzed during the present study are included in this
489 published article and its Supplementary Information files (preprint available on BioRxiv
490 (BIORXIV/2020.10.02.324061). Additional information related to this paper may be requested
491 from the authors.

492

493 **Competing Interests**

494 The authors declare no competing interests.

495

496 **Acknowledgements**

497 The authors gratefully acknowledge support from the EU (BIODESIGN FP7-NMP-2012-262948
498 and ERC Advanced MechAGE ERC-2016-ADG-741883). E. Wehrle received funding from the
499 ETH Postdoctoral Fellowship Program (MSCA-COFUND, FEL-25_15-1).

500

501 **References**

- 502 1 Giannoudis, P., Tzioupis, C., Almalki, T. & Buckley, R. Fracture healing in osteoporotic fractures:
503 is it really different? A basic science perspective. *Injury* **38 Suppl 1**, S90-99,
504 doi:10.1016/j.injury.2007.02.014 (2007).
- 505 2 Syed, A. A., Agarwal, M., Giannoudis, P. V., Matthews, S. J. E. & Smith, R. M. Distal femoral
506 fractures: long-term outcome following stabilisation with the LISS. *Injury-International Journal*
507 *of the Care of the Injured* **35**, 599-607, doi:10.1016/S0020-1383(03)00247-X (2004).
- 508 3 Winkler, T., Sass, F. A., Duda, G. N. & Schmidt-Bleek, K. A review of biomaterials in bone defect
509 healing, remaining shortcomings and future opportunities for bone tissue engineering THE
510 UNSOLVED CHALLENGE. *Bone Joint Res* **7**, 232-243, doi:10.1302/2046-3758.73.Bjr-2017-
511 0270.R1 (2018).
- 512 4 Przekora, A. The summary of the most important cell-biomaterial interactions that need to be
513 considered during in vitro biocompatibility testing of bone scaffolds for tissue engineering
514 applications. *Mat Sci Eng C-Mater* **97**, 1036-1051, doi:10.1016/j.msec.2019.01.061 (2019).
- 515 5 Stevens, M. M. Biomaterials for bone tissue engineering. *Mater Today* **11**, 18-25, doi:Doi
516 10.1016/S1369-7021(08)70086-5 (2008).
- 517 6 Hulsart-Billstrom, G. *et al.* A Surprisingly Poor Correlation between in Vitro and in Vivo Testing
518 of Biomaterials for Bone Regeneration: Results of a Multicentre Analysis. *Eur Cells Mater* **31**,
519 312-322, doi:10.22203/eCM.v031a20 (2016).
- 520 7 Pearce, A. I., Richards, R. G., Milz, S., Schneider, E. & Pearce, S. G. Animal models for implant
521 biomaterial research in bone: A review. *Eur Cells Mater* **13**, 1-10 (2007).
- 522 8 Peric, M. *et al.* The rational use of animal models in the evaluation of novel bone regenerative
523 therapies. *Bone* **70**, 73-86, doi:10.1016/j.bone.2014.07.010 (2015).

- 524 9 Gomes, P. S. & Fernandes, M. H. Rodent models in bone-related research: the relevance of
525 calvarial defects in the assessment of bone regeneration strategies. *Lab Anim-Uk* **45**, 14-24,
526 doi:10.1258/la.2010.010085 (2011).
- 527 10 Harris, J. S., Bemenderfer, T. B., Wessel, A. R. & Kacena, M. A. A review of mouse critical size
528 defect models in weight bearing bones. *Bone* **55**, 241-247, doi:10.1016/j.bone.2013.02.002
529 (2013).
- 530 11 Holstein, J. H. *et al.* Mouse Models for the Study of Fracture Healing and Bone Regeneration.
531 *Osteoporosis Research: Animal Models*, 175-191, doi:10.1007/978-0-85729-293-3_14 (2011).
- 532 12 Horner, E. A. *et al.* Long Bone Defect Models for Tissue Engineering Applications: Criteria for
533 Choice. *Tissue Eng Part B-Re* **16**, 263-271, doi:10.1089/ten.teb.2009.0224 (2010).
- 534 13 van Griensven, M. Preclinical testing of drug delivery systems to bone. *Adv Drug Deliver Rev*
535 **94**, 151-164, doi:10.1016/j.addr.2015.07.006 (2015).
- 536 14 Gauthier, O. *et al.* In vivo bone regeneration with injectable calcium phosphate biomaterial: A
537 three-dimensional micro-computed tomographic, biomechanical and SEM study. *Biomaterials*
538 **26**, 5444-5453, doi:10.1016/j.biomaterials.2005.01.072 (2005).
- 539 15 Martino, M. *et al.* Growth factors engineered for super-affinity to extracellular matrix enhance
540 tissue healing. *J Tissue Eng Regen M* **8**, 35-36 (2014).
- 541 16 Meinel, L. *et al.* Silk based biomaterials to heal critical sized femur defects. *Bone* **39**, 922-931,
542 doi:10.1016/j.bone.2006.04.019 (2006).
- 543 17 Lienemann, P. S. *et al.* Longitudinal in vivo evaluation of bone regeneration by combined
544 measurement of multi-pinhole SPECT and micro-CT for tissue engineering (vol 5, 10238, 2015).
545 *Sci Rep-Uk* **5**, doi:ARTN 1239110.1038/srep12391 (2015).
- 546 18 van Lenthe, G. H. *et al.* Nondestructive micro-computed tomography for biological imaging
547 and quantification of scaffold-bone interaction in vivo. *Biomaterials* **28**, 2479-2490,
548 doi:10.1016/j.biomaterials.2007.01.017 (2007).
- 549 19 Boerckel, J. D. *et al.* Effects of protein dose and delivery system on BMP-mediated bone
550 regeneration. *Biomaterials* **32**, 5241-5251, doi:10.1016/j.biomaterials.2011.03.063 (2011).
- 551 20 Mehta, M., Checa, S., Lienau, J., Hutmacher, D. & Duda, G. N. In Vivo Tracking of Segmental
552 Bone Defect Healing Reveals That Callus Patterning Is Related to Early Mechanical Stimuli. *Eur*
553 *Cells Mater* **24**, 358-371, doi:DOI 10.22203/eCM.v024a26 (2012).
- 554 21 Tourolle né Betts, D. C., Wehrle, E., Paul, G. R., Kuhn, G. A., Christen, P., Hofmann, S. & Müller,
555 R. The association between mineralised tissue formation and the mechanical local in vivo
556 environment: Time-lapsed quantification of a mouse defect healing model. *Sci Rep-Uk* **10**,
557 1100, doi:doi: <https://doi.org/10.1038/s41598-020-57461-5> (2020).
- 558 22 Wehrle, E., Tourolle né Betts, D. C., Kuhn, G. A., Scheuren, A.C., Hofmann, S. & Müller, R.
559 Evaluation of longitudinal time-lapsed in vivo micro-CT for monitoring fracture healing in
560 mouse femur defect models. *Sci Rep-Uk* **9**, 17445, doi:doi: <https://doi.org/10.1038/s41598-019-53822-x> (2019).
- 562 23 Zwingenberger, S. *et al.* Establishment of a femoral critical-size bone defect model in
563 immunodeficient mice. *J Surg Res* **181**, E7-E14, doi:10.1016/j.jss.2012.06.039 (2013).
- 564 24 Borgiani, E. *et al.* Age-Related Changes in the Mechanical Regulation of Bone Healing Are
565 Explained by Altered Cellular Mechanoreponse. *J Bone Miner Res*, doi:10.1002/jbmr.3801
566 (2019).
- 567 25 Al-Tamimi, A. A., Peach, C., Fernandes, P. R., Cseke, A. & Bartolo, P. J. D. S. Topology
568 Optimization to reduce the stress shielding effect for orthopedic applications. *Proc Cirp* **65**,
569 202-206, doi:10.1016/j.procir.2017.04.032 (2017).
- 570 26 Boby, J. D. *et al.* The effect of stem stiffness on femoral bone resorption after canine porous-
571 coated total hip arthroplasty. *Clin Orthop Relat Res*, 196-213 (1990).

- 572 27 Zhang, D. W., Wu, X. W., Chen, J. D. & Lin, K. L. The development of collagen based composite
573 scaffolds for bone regeneration. *Bioact Mater* **3**, 129-138,
574 doi:10.1016/j.bioactmat.2017.08.004 (2018).
- 575 28 Ferreira, A. M., Gentile, P., Chiono, V. & Ciardelli, G. Collagen for bone tissue regeneration.
576 *Acta Biomater* **8**, 3191-3200, doi:10.1016/j.actbio.2012.06.014 (2012).
- 577 29 Glowacki, J. & Mizuno, S. Collagen scaffolds for tissue engineering. *Biopolymers* **89**, 338-344,
578 doi:10.1002/bip.20871 (2008).
- 579 30 Hertweck, J. *et al.* CD34(+) cells seeded in collagen scaffolds promote bone formation in a
580 mouse calvarial defect model. *J Biomed Mater Res B Appl Biomater* **106**, 1505-1516,
581 doi:10.1002/jbm.b.33956 (2018).
- 582 31 Stuckensen, K. *et al.* Anisotropic Cryostructured Collagen Scaffolds for Efficient Delivery of
583 RhBMP-2 and Enhanced Bone Regeneration. *Materials (Basel)* **12**, doi:10.3390/ma12193105
584 (2019).
- 585 32 Cipitria, A. *et al.* BMP delivery complements the guiding effect of scaffold architecture without
586 altering bone microstructure in critical-sized long bone defects: A multiscale analysis. *Acta*
587 *Biomater* **23**, 282-294, doi:10.1016/j.actbio.2015.05.015 (2015).
- 588 33 Sarkar, M. R. *et al.* Bone formation in a long bone defect model using a platelet-rich plasma-
589 loaded collagen scaffold. *Biomaterials* **27**, 1817-1823, doi:10.1016/j.biomaterials.2005.10.039
590 (2006).
- 591 34 Karageorgiou, V. & Kaplan, D. Porosity of 3D biomaterial scaffolds and osteogenesis.
592 *Biomaterials* **26**, 5474-5491, doi:10.1016/j.biomaterials.2005.02.002 (2005).
- 593 35 Luo, Z. W. *et al.* Effect of Pore Size on the Biodegradation Rate of Silk Fibroin Scaffolds. *Adv*
594 *Mater Sci Eng*, doi:Artn 31539710.1155/2015/315397 (2015).
- 595 36 Begam, H., Nandi, S. K., Kundu, B. & Chanda, A. Strategies for delivering bone morphogenetic
596 protein for bone healing. *Mat Sci Eng C-Mater* **70**, 856-869, doi:10.1016/j.msec.2016.09.074
597 (2017).
- 598 37 Salazar, V. S., Gamer, L. W. & Rosen, V. BMP signalling in skeletal development, disease and
599 repair. *Nat Rev Endocrinol* **12**, 203-221, doi:10.1038/nrendo.2016.12 (2016).
- 600 38 Gothard, D. *et al.* Tissue Engineered Bone Using Select Growth Factors: A Comprehensive
601 Review of Animal Studies and Clinical Translation Studies in Man. *Eur Cells Mater* **28**, 166-208,
602 doi:DOI 10.22203/eCM.v028a13 (2014).
- 603 39 James, A. W. *et al.* A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.
604 *Tissue Eng Part B-Re* **22**, 284-297, doi:10.1089/ten.teb.2015.0357 (2016).
- 605 40 Skovrlj, B. *et al.* Association Between BMP-2 and Carcinogenicity. *Spine* **40**, 1862-1871,
606 doi:10.1097/Brs.0000000000001126 (2015).
- 607 41 Tannoury, C. A. & An, H. S. Complications with the use of bone morphogenetic protein 2 (BMP-
608 2) in spine surgery. *Spine J* **14**, 552-559, doi:10.1016/j.spinee.2013.08.060 (2014).
- 609 42 Schmidt-Bleek, K., Willie, B. M., Schwabe, P., Seemann, P. & Duda, G. N. BMPs in bone
610 regeneration: Less is more effective, a paradigm-shift. *Cytokine Growth F R* **27**, 141-148,
611 doi:10.1016/j.cytogfr.2015.11.006 (2016).
- 612 43 Karageorgiou, V. *et al.* Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic
613 protein-2 in vitro and in vivo. *J Biomed Mater Res A* **78**, 324-334, doi:10.1002/jbm.a.30728
614 (2006).
- 615 44 Zhang, W. *et al.* VEGF and BMP-2 promote bone regeneration by facilitating bone marrow stem
616 cell homing and differentiation. *Eur Cell Mater* **27**, 1-11; discussion 11-12,
617 doi:10.22203/ecm.v027a01 (2014).
- 618 45 Hollinger, J. O. *et al.* Recombinant human bone morphogenetic protein-2 and collagen for
619 bone regeneration. *J Biomed Mater Res* **43**, 356-364, doi:10.1002/(sici)1097-
620 4636(199824)43:4<356::aid-jbm3>3.0.co;2-7 (1998).

- 621 46 Herberg, S. *et al.* Combinatorial morphogenetic and mechanical cues to mimic bone
622 development for defect repair. *Sci Adv* **5**, doi:ARTN eaax247610.1126/sciadv.aax2476 (2019).
623 47 Fragogeorgi, E. A. *et al.* In vivo imaging techniques for bone tissue engineering. *J Tissue Eng* **10**,
624 doi:Artn 204173141985458610.1177/2041731419854586 (2019).
625 48 Gil, C. J. *et al.* In Vivo Tracking of Tissue Engineered Constructs. *Micromachines-Basel* **10**,
626 doi:ARTN 47410.3390/mi10070474 (2019).
627 49 Li, K. & Liu, B. Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic
628 imaging. *Chem Soc Rev* **43**, 6570-6597, doi:10.1039/c4cs00014e (2014).
629 50 Mafina, M. K., Sullivan, A. C. & Hing, K. A. Use of a fluorescent probe to monitor the enhanced
630 affinity of rh-BMP-2 to silicated-calcium phosphate synthetic bone graft substitutes under
631 competitive conditions. *Mat Sci Eng C-Mater* **80**, 207-212, doi:10.1016/j.msec.2017.05.142
632 (2017).
633 51 Hulsart-Billstrom, G. *et al.* Non-invasive tri-modal visualisation via PET/SPECT/mu CT of
634 recombinant human bone morphogenetic protein-2 retention and associated bone
635 regeneration: A proof of concept. *J Control Release* **285**, 178-186,
636 doi:10.1016/j.jconrel.2018.07.012 (2018).
637 52 Taylor, C., Scheuren, A., Trüssel, A. & Müller R. 3D local in vivo environment (LivE) imaging for
638 single cell protein analysis of bone tissue. *Current Directions in Biomedical Engineering* **2**
639 (2016).
640 53 Wehrle E., Paul G. R., Betts D. C., Kuhn G. A. & Müller R. Individualized cyclic mechanical loading
641 improves callus properties in novel femur fracture loading model as assessed by time-lapsed
642 in vivo imaging and real-time micro-finite element analysis. *Trans. Orthop. Res. Soc.* **44**, 1526
643 (2019).

644

645 **Figure legends**

646 **Figure 1.** Representative images (threshold: 645 mg HA/cm³) of the defect region from animals
647 of the 0.9mm group (top) and the 2.0mm group (bottom).
648 Visualization of bone formation (orange) and resorption (blue) via registration of micro-CT
649 scans from weeks 1-6 to weeks 0-5.

650 **Figure 2.** Micro-CT based evaluation of bone parameters in the 0.9mm group (blue) and the
651 2.0mm group (red) using different VOIS: defect center (DC; a-c), defect periphery (DP; d-f),
652 cortical fragment center (FC; g-i), cortical fragment periphery (FP; j-l). a, d, g, j: Bone formation
653 rate (solid line) and bone resorption rate (dashed line) given in percent per day. b, e, h, k: Bone
654 volume (BV) normalized to TV (DC for DC and DP, FC for FC+FP). c, f, i, l: Degree of bone
655 mineralization given as ratio of bone volume with a density ≥ 645 mg HA/cm³ to the total

656 osseous volume (threshold ≥ 395 mg HA/cm³). n=7/10; a,d,g,j: * indicates $p < 0.05$ between
657 consecutive weeks; # indicates $p < 0.05$ between groups. b,c,e,f,h,i,k,l: * indicates $p < 0.05$
658 between groups; # indicates $p < 0.05$ between consecutive weeks.

659 **Figure 3.** Representative images (threshold: 645 mg HA/cm³) of the defect region from animals
660 of the collagen group (top) and the collagen+BMP-2 group (bottom). Visualization of bone
661 formation (orange) and resorption (blue) via registration of micro-CT scans from weeks 1-6 to
662 weeks 0-5.

663 **Figure 4.** Micro-CT based evaluation of bone parameters in the collagen group (blue) and the
664 collagen+BMP-2 group (red) using different VOIS: defect center (DC; a-c), defect periphery
665 (DP; d-f), cortical fragment center (FC; g-i), cortical fragment periphery (FP; j-l). a, d, g, j: Bone
666 formation rate (solid line) and bone resorption rate (dashed line) given in percent per day. b,
667 e, h, k: Bone volume (BV) normalized to TV (DC for DC and DP, FC for FC+FP). c, f, i, l: Degree
668 of bone mineralization given as ratio of bone volume with a density ≥ 645 mg HA/cm³ to the
669 total osseous volume (threshold ≥ 395 mg HA/cm³). n=7/10; a,d,g,j: * indicates $p < 0.05$
670 between consecutive weeks; # indicates $p < 0.05$ between groups. b,c,e,f,h,i,k,l: * indicates p
671 < 0.05 between groups; # indicates $p < 0.05$ between consecutive weeks.

672 **Figure 5.** Histology of longitudinal sections of fractured femora 6 weeks after defect surgery.
673 Row 1: Safranin-O staining of 0.9mm and 2.0mm defect groups - overview images, scale bar =
674 1 mm and area between inner pins of fixator, scale bar = 100 μ m. Row 2: Safranin-O staining
675 of collagen and collagen+BMP-2 groups - overview images, scale bar = 1 mm and area between
676 inner pins of fixator, scale bar = 100 μ m. Row 3: Sirius-Red staining of collagen and
677 collagen+BMP-2 groups - overview images, scale bar = 1 mm and area centered between inner

678 pins of fixator, scale bar = 100 μm . Row 4: Sirius-Red staining of defect center of collagen group
679 and collagen+BMP-2 group, scale bar = 50 μm . Row 5: Sirius-Red staining of original collagen
680 matrix, scale bar = 500 μm (left image) and 50 μm (right image).

681

682

683

684

685

686 **Tables**

687 **Table 1.** Number of bridged cortices per callus evaluated weekly in two perpendicular planes
 688 and number of mice with successful fracture healing in the 0.9mm and the 2.0mm defect
 689 groups (≥ 3 bridged cortices, threshold 395 mg HA/cm³).

Week	Group	Number of bridged cortices					Fracture healing outcome	
		0	1	2	3	4	Not healed	Healed
0	0.9mm	10	0	0	0	0	10	0
	2.0mm	8	0	0	0	0	8	0
1	0.9mm	10	0	0	0	0	10	0
	2.0mm	8	0	0	0	0	8	0
2	0.9mm	7	3	0	0	0	10	0
	2.0mm	8	0	0	0	0	10	0
3	0.9mm	1	0	2	6	1	3	7
	2.0mm	7	1	0	0	0	8	0
4	0.9mm	1	0	1	5	3	2	8
	2.0mm	7	0	0	1	0	7	1
5	0.9mm	1	0	0	4	5	1	9
	2.0mm	7	0	0	1	0	7	1
6	0.9mm	1	0	0	4	5	1	9
	2.0mm	7	0	0	1	0	7	1

690

691

692

693

694

695 **Table 2.** Number of bridged cortices per callus evaluated weekly in two perpendicular planes
 696 and number of mice with successful fracture healing in the collagen and the collagen+BMP-2
 697 groups (≥ 3 bridged cortices, threshold 395 mg HA/cm³).

698

Week	Group	Number of bridged cortices					Fracture healing outcome	
		0	1	2	3	4	Not healed	Healed
0	collagen	8	0	0	0	0	8	0
	collagen+BMP	8	0	0	0	0	8	0
1	collagen	8	0	0	0	0	8	0
	collagen+BMP	8	0	0	0	0	8	0
2	collagen	7	0	1	0	0	8	0
	collagen+BMP	0	0	0	0	8	0	8
3	collagen	7	0	0	1	0	7	1
	collagen+BMP	0	0	0	0	8	0	8
4	collagen	7	0	0	1	0	7	1
	collagen+BMP	0	0	0	0	8	0	8
5	collagen	7	0	0	1	0	7	1
	collagen+BMP	0	0	0	0	8	0	8
6	collagen	7	0	0	1	0	7	1
	collagen+BMP	0	0	0	0	8	0	8

699

700

Figure 1




Figure 2



















Figure 3




Figure 4


















Figure 5

